Genetics can be used to predict a patient’s response to Antipsychotic Medications treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online in the American Journal of Psychiatry.
Schizophrenia is one of the leading causes of disability in the U.S. It is characterized by delusions, hallucinations and disorganized thoughts and behavior. The condition is currently treated with antipsychotic drugs, but this therapy is given without guidance from lab tests to show effectiveness, as is common in other areas of medicine. Doctors often use “trial-and-error” when choosing a treatment for schizophrenia, without knowing if patients will respond well. This uncertainty places a large burden on not only patients and their families, but also health care professionals and health care systems.